{"id":"6ccc91fc60d0","type":"article","url":"https://hartvaat.nl/2016/11/01/intensieve-bloeddrukbehandeling-120-80-mmhg-bij-cardiovasculair-risico-protagoni/","title":"Intensieve bloeddrukbehandeling <120/80 mmHg bij cardiovasculair risico: protagonist-standpunt","title_en":"Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? A Protagonist View From the SPRINT Trial (Systolic Blood Pressure Intervention Trial).","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["biomarkers-cardiovasculair","bloeddrukbehandeling","obesitas"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.116.023263","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.116.023263","authors":["Suzanne Oparil","Cora E Lewis"],"significance":7,"published":"2016-11-01","source_date":"2016-11-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"This pro perspective argued for intensive blood pressure treatment to <120/80 mmHg in patients with cardiovascular risk factors, based on SPRINT evidence and the continuous relationship between blood pressure and cardiovascular risk.","created":"2026-07-03T10:26:24Z","updated":"2026-07-03T13:25:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Pro-argumentatie voor intensieve bloeddrukbehandeling tot <120/80 mmHg bij patiënten met cardiovasculaire risicofactoren, gebaseerd op de SPRINT-resultaten.","abstract_original":""}